How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,393 results for

Six Item Cognitive Impairment Test

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Putative Cognitive Enhancer VU319

): Paul Newhouse, Vanderbilt University Medical Center Study Details Study Description Go to Brief Summary: This is a safety study of the molecule VU319 to ascertain pharmacokinetic and pharmacodynamic data and test cognitive enhancement in healthy volunteers. Condition or disease Intervention/treatment Phase Cognitive Impairment Drug: Single Dose of VU319 Drug: Single Dose Placebo Other: Fed State Other: Fasted State Drug: Dose Escalation of VU319 Drug: Placebo Dose Escalation Phase 1 Detailed (...) the examination of acquisition, encoding and retrieval. This standard test has been widely used in studies of cognitive impairment and offers measures of storage into and retrieval from both short term and long-term memory and intrusion errors. In addition to the measures of recall, recall failure, and consistency we add a long-delay (20 min.) recall trial and a recognition trial to assess discrimination and response bias. This task shows excellent predictive validity and test-retest reliability. We have 10

2017 Clinical Trials

102. Evaluation of a Cognitive Psychophysiological Treatment for Tourette Syndrome and Tic Disorders

and cognitive aspects involved in adequate planning of action in a variety of everyday situations involving routing, complex tasks and both anticipation and enactment. change in dimensions of perfectionism and use as a predictive variable of treatment issues [ Time Frame: baseline ] The Frost Multidimensional Perfectionism Scale is a self-administered questionnaire of 35 items covering six dimensions of perfectionism. change in dimensions of perfectionism [ Time Frame: change from baseline ] The Frost (...) home practice and received strategies for the future. Behavioral: Cognitive psychophysiological Focus on the processes influencing thoughts and behaviors underlying tics. Other Name: CoPs Outcome Measures Go to Primary Outcome Measures : Yale Global Tic Severity Scale (YGTSS) [ Time Frame: baseline ] The YGTSS is a clinician-rated scale used to assess change in tic severity and impairment due to tics. Secondary Outcome Measures : determine style of planning actions [ Time Frame: baseline

2017 Clinical Trials

103. Promoting Independent Living in Frail Older Adults by Improving Cognition and Gait Ability and Using Assistive Products

to Additional Information: Publications: Paiva, Diana S; Apóstolo, João L. A. 2015. Estudo de adaptação transcultural e validação do Six Item Cognitive Impairment Test . In J. Apóstolo & M. Almeida (Eds). Elderly Health Care Nursing. Monographic Series - Health Sciences Education and Research, 3 - 18. ISBN: 978-989-99426-1-5. Coimbra: Unidade de Investigação em Ciências da Saúde: Enfermagem (UICISA: E) ESEnfC. Bandeira, M. L., Azevedo, A. B., Gomes, C. S., Tomé, L. P., Mendes, M. F., Baptista, M. I (...) program. Moreover, an auto-blocking mechanism for rolling walkers will be developed and implemented in this study. The results of the study and all the material that was used, will be disseminated in a web platform. Condition or disease Intervention/treatment Phase Frailty Cognition Mild Cognitive Impairment Other: Combined Intervention Group Not Applicable Detailed Description: In this growing context of aging societies, the number of institutionalized older adults tends to increase. Several reasons

2017 Clinical Trials

104. Integrated Cognitive, Sensory, and Motor Rehabilitation of Hand Functions

the intervention. Device: Robotic Glove Device: Electrical Stimulation Outcome Measures Go to Primary Outcome Measures : Motricity Index [ Time Frame: 9 weeks ] Outcome measure to evaluate motor impairment after stroke; subscale for arm only; the subscale ranges from 0 (maximal impairment) to 100 (no impairment). Secondary Outcome Measures : Action Research Arm Test [ Time Frame: baseline; 9 weeks; 13 weeks. ] 19-items outcome measure divided into 4 sub-tests (grasp, grip, pinch, and gross arm movement (...) ). Performance on each item is rated on a 4-point ordinal scale ranging from: 3: Performs test normally 2: Completes test, but takes abnormally long or has great difficulty 1: Performs test partially 0: Can perform no part of test Medical Research Council [ Time Frame: baseline, 9 weeks, 13 weeks. ] A standardized assessment to measure muscle strength; Score range 0-5 (minimum 0, maximum 5) 3: Performs test normally 2: Completes test, but takes abnormally long or has great difficulty 1: Performs test

2017 Clinical Trials

105. Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury

. Condition or disease Intervention/treatment Phase Major Depressive Disorder Traumatic Brain Injury Behavioral: Cognitive Behavioral Therapy for individuals with TBI Other: Waitlist Control Not Applicable Detailed Description: The primary aim of this study is to develop a highly acceptable, manualized treatment (CBTx-TBI) for MDD in patients with moderate to severe TBI. After developing the manual (Phase 1), a nonrandomized trial (Phase 2) will be conducted to test its acceptability and tolerability (...) Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

106. Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related

activities, social relationships, and nutrition, and how these difficulties relate to biological rhythms Addenbrooke's Cognitive Examination (ACE-R) [ Time Frame: Baseline (T0), and change from baseline at three (T4) and six (T7) months ] short cognitive test, which evaluates five cognitive domains: attention/orientation, memory, verbal fluency, language, visual-spatial abilities. The test, with a maximum score of 100 and a mild cognitive impairment cut-off of 66, includes the Mini Mental State (...) Mania scale); BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry). Assessment of Quality of Life: SF-12 (Short Form Health Survey-12 items). Neuropsychological screening: l) Addenbrooke's Cognitive Examination (ACE-R). Neuropsychiatric screening (treatment-) Subjects affected by chronic hepatitis HCV-related, in wait list for new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests Other: Neuropsychiatric screening Psychiatric

2017 Clinical Trials

107. Omega-3 Fatty Acids and Exercise on Mobility and Cognition in Older Women

, spatial working memory, executive function and processing speed are assessed via a battery of cognitive tests. Mobility testing comprises three walking tests, some under single and dual task paradigms, as well as the five times sit to stand test, a measure of dynamic balance and functional mobility. Volunteers also provide two blood samples, one for fatty acids analysis and the other serum homocysteine levels. Participants also complete health-related quality of life questionnaire, the short form 36 (...) Omega-3 Fatty Acids and Exercise on Mobility and Cognition in Older Women Omega-3 Fatty Acids and Exercise on Mobility and Cognition in Older Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Omega-3

2017 Clinical Trials

108. Effects of Glucocorticoids on Cognition in HIV-infected Women

University Collaborator: National Institute of Mental Health (NIMH) Information provided by (Responsible Party): Johns Hopkins University Study Details Study Description Go to Brief Summary: Despite treatment with antiretroviral therapy, women living with HIV continue to experience cognitive impairment. Psychological risk factors, including stress, impair cognition more in HIV-infected women than HIV-uninfected women. This study plans to examine a novel intervention for cognitive dysfunction that targets (...) weeks on cognition and side effects. The clinical trial will include 100 virally suppressed HIV+ women who show elevated stress and cognitive impairment and who represent the range of psychological risk factors characteristic of this population. Next, to understand the mechanism and broader clinical significance of LDH on cognition, investigators will conduct a 4-week randomized study of the effects of daily treatment with LDH versus placebo on cognition in HIV+ women (targeted n=80). Women meeting

2017 Clinical Trials

109. Non-cardiac Chest Pain: Effect of Cognitive Therapy Administered as Guided Self-help

Information provided by (Responsible Party): Sorlandet Hospital HF Study Details Study Description Go to Brief Summary: This study aims to test an easily implementable web-based cognitive behaviour therapy (CBT) self-help intervention designed for non-cardiac chest pain patients, and compare effectiveness and cost-effectiveness to treatment as usual in an randomized controlled trial (RCT). Condition or disease Intervention/treatment Phase Chest Pain Behavioral: Guided self-help Not Applicable Detailed (...) : 18 Years to 70 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Non-Cardiac Chest Pain Exclusion Criteria: Language difficulties Unable to perform at least moderate physical activity due to physical constraints Obvious cognitive impairment (e.g mentally retarded, psychotic, dementia or intoxicated) no regular access to a computer/tablet computer with internet connection Contacts and Locations Go to Information from the National

2017 Clinical Trials

110. Effects of Horticultural Therapy on Elderly at Risk of Cognitive Decline

) at baseline and at 9 months [ Time Frame: Baseline, 9 months ] Clinical Dementia Rating (CDR ) is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment & Problem Solving, Community Affairs, Home & Hobbies, and Personal Care. Changes in Colour Trails Tests (CTT) scores at baseline, 3 months and 9 months [ Time Frame: Baseline, 3 months, 9 months ] Colour Trails Tests (CTT) 1 and 2 (...) Eligible for Study: 60 Years to 100 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: 1. Community-living elderly aged 60 years and above, AND 2. Mild Cognitive Impairment based on clinical history and neuropsychological test scores (Z score <0 and >-1.5), OR Subjective Memory Impairment based on self-report, OR (C) 2 or more risk factors for dementia such as family history, cerebrovascular disease, and cardiovascular risk factors

2017 Clinical Trials

111. Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)

task to test for memory consolidation and a maze test for executive performance. Each item is scored and then the item scores are totaled. Total scores range from 0 (best) to 90 (worst). Higher scores indicate greater cognitive impairment. A negative change from Baseline indicates improvement. Analysis of Covariance (ANCOVA) model was used for analyses that included treatment, pooled centre, and their interaction as factors and Baseline ADAS-cog+ score as a covariate. Secondary Outcome Measures (...) , a delayed recall task to test for memory consolidation and a maze test for executive performance. Each item is scored and then the item scores are totaled. Total scores range from 0 (best) to 90 (worst). Higher scores indicate greater cognitive impairment. A negative change from Baseline indicates improvement. ANCOVA model was used for analyses that included treatment, pooled centre, and their interaction as factors and Baseline ADAS-cog+ score as a covariate. Change From Baseline in Montreal Cognitive

2012 Clinical Trials

112. Robot-assisted therapy for long-term upper limb impairment after stroke

. Nearly all patients are disabled immediately following a stroke event. Common disabilities include permanent paralysis of one side of the body, speech or swallowing difficulties, problems with memory, personality changes or a range of other difficulties. Depression, anxiety and cognitive impairment are also common after stroke. By the end of the first year, about half of all survivors of stroke remain dependent on others for activities of daily living. Stroke mainly affects older people (...) paralysis restricted to one side of the body 6 Robot-assisted therapy for upper limb impairment after stroke: November 2010 on patients in the acute and subacute phase of their stroke (= 3 months) and those in the chronic phase (>3 months duration). The primary and secondary outcomes of the included studies were an improvement in daily living activity and changes in arm motor function impairment, respectively. The methodological quality of the included studies was assessed using the PEDro scale. 5 Six

2011 Australia and New Zealand Horizon Scanning Network

113. Effect of computerized cognitive rehabilitation program on cognitive function and activities of living in stroke patients. (Full text)

Effect of computerized cognitive rehabilitation program on cognitive function and activities of living in stroke patients. [Purpose] The objective of this study was to examine the effect of cognitive rehabilitation using a computer on cognitive function and activities of daily living in stroke patients presenting impairment of cognitive function. [Subjects] Forty-six stroke patients were divided into two groups (a training group and control group) through random assignment. [Methods (...) ] The training group received rehabilitation therapy and an additional computerized cognitive rehabilitation program using The RehaCom software 30 minutes/day, 5 times/week for 5 weeks. The control group received only rehabilitation therapy including physical and occupational therapy. A comparative analysis on all subjects was conducted before and after the experiment using a cognitive test and activities of daily living test. [Results] After 5 weeks of therapy, the training group presented statistically

2015 Journal of physical therapy science Controlled trial quality: uncertain PubMed abstract

114. Managing Anxiety From Cancer (MAC): Testing an Intervention for Anxiety in Older Adults With Cancer and Their Caregivers

weak or cognitively impaired to participate in the intervention and complete the assessments Per self-report/screening measures, has received cognitive-behavioral therapy since cancer diagnosis As per medical record or self-report, currently being treated for schizophrenia, substance use or dependence, and/or bi-polar disorder Anxiety due solely to a medical procedure as determined by a patient-report item on the screening questionnaire CAREGIVERS: Endorsing active suicidal ideation on the item (...) Managing Anxiety From Cancer (MAC): Testing an Intervention for Anxiety in Older Adults With Cancer and Their Caregivers Managing Anxiety From Cancer (MAC): Testing an Intervention for Anxiety in Older Adults With Cancer and Their Caregivers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2017 Clinical Trials

115. Reliability and Physiological Analysis of an Isometric Test of Localized Muscular Fatigue

on the average of the answers to these six questions, in order to obtain an overall sleep problems score Need for Recovery Scale [ Time Frame: Day 7 ] This is an 11 item scale which aims to evaluate work fatigue symptoms, related to a series of emotional, cognitive and behavioral aspects characterized as temporary overload feelings, irritability, social seclusion, lack of energy for new efforts and performance reduction Borg Scale [ Time Frame: Day 7 ] Participants' physical effort perception will also (...) 1 ] This scale is intended to evaluate participants' sleep and tiredness, which consists in six questions about sleep issues in the previous month. Questions are about (1) problems initiating sleep, (2) awakening from sleep, (3) early morning awakening, (4) not feeling adequately rested, (5) experiencing daytime impairment and (6) being dissatisfied with sleep. To each question participants will answer on a zero to seven days a week scale. The quantity of days will be calculated based

2017 Clinical Trials

116. This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

baseline in everyday functional capacity as measured by Schizophrenia Cognition Rating Scale (SCoRS) total score after 24 and 52 weeks of treatment [ Time Frame: Baseline, Week 24 and Week 52 ] Change from baseline in the BAC App composite T score after 52 weeks of treatment [ Time Frame: Baseline and Week 52 ] Change from baseline in Positive and Negative Syndrome Scale (PANSS) positive items score, negative items score, and total score after 52 weeks of treatment [ Time Frame: Baseline and Week 52 (...) This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year - Full Text View

2017 Clinical Trials

117. Testing if Reductions in Negative Affect Yield Decreased Emotional Eating Symptoms

) Actual Enrollment : 28 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment Official Title: Testing if Reductions in Negative Affect Yield Decreased Emotional Eating Symptoms: A Cognitive Bias Intervention Actual Study Start Date : March 28, 2017 Actual Primary Completion Date : May 3, 2017 Actual Study Completion Date : May 3, 2017 Arms and Interventions Go to Arm Intervention/treatment Experimental: Cognitive Bias (...) being tested by other researchers utilizing cognitive bias modification paradigms. The relaxation training sessions will be matched to the length of the treatment condition and therefore will last approximately 30 minutes. Outcome Measures Go to Primary Outcome Measures : Change in Emotional Overeating Questionnaire Scores [ Time Frame: Assessed at baseline (time zero), mid-treatment (8 days after baseline), and post-treatment (2 weeks after baseline). ] Emotional eating will be measured using the 6

2017 Clinical Trials

118. Validation, Reliability and Pilot Test of the Personalized Exercise Questionnaire (PEQ)

-Square test. Secondary Outcome Measures : Preferences to exercise [ Time Frame: 3 months ] Using the PEQ, domains two and four, will be used to quantify the frequency of each preference. Results will be presented in a table with column one representing the survey item and column two representing the frequency of the reported outcome. Barriers to exercise [ Time Frame: 3 months ] Using the PEQ, domain six, will be used to quantify the frequency of each barrier. Results will be presented in a table (...) and/or steroid use. The participant is diagnosed with a reading disability or dyslexia The participant has a cognitive impairment of some severity as to adversely affect the validity of the data Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03125590

2017 Clinical Trials

119. Trajectory of Cognitive Decline After Incident Stroke. (Full text)

) cohort, residing in the continental United States, enrolled 2003-2007 and followed up through March 31, 2013. Over a median follow-up of 6.1 years (interquartile range, 5.0-7.1 years), 515 participants survived expert-adjudicated incident stroke and 23,057 remained stroke free.Time-dependent incident stroke.The primary outcome was change in global cognition (Six-Item Screener [SIS], range, 0-6). Secondary outcomes were change in new learning (Consortium to Establish a Registry for Alzheimer Disease (...) Word-List Learning; range, 0-30), verbal memory (Word-List Delayed Recall; range, 0-10), and executive function (Animal Fluency Test; range, ≥0), and cognitive impairment (SIS score <5 [impaired] vs ≥5 [unimpaired]). For all tests, higher scores indicate better performance.Stroke was associated with acute decline in global cognition (0.10 points [95% CI, 0.04 to 0.17]), new learning (1.80 points [95% CI, 0.73 to 2.86]), and verbal memory (0.60 points [95% CI, 0.13 to 1.07]). Participants

2015 JAMA PubMed abstract

120. Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status

), three symptom scales (fatigue, vomiting and pain) and six single item scales (dyspnea, insomnia, constipation, anorexia, diarrhea, and financial difficulties). Health-related quality of life using QLQ-BN20 [ Time Frame: at baseline and every month until 12 months ] The QLQ-BN20 questionnaire includes 20 items covering functional deficits, symptoms, toxic effects of treatment, and uncertainty about the future. Cognitive assessment MMSEs [ Time Frame: at baseline and they were repeated every month (...) months ] Assessment every 2 weeks until 12 months by physical and neurological examinations, complete blood counts and urine strip tests. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTCAE, version 3.0). Health-related quality of life using QLQ-C30 questionnaire [ Time Frame: at baseline and every month until 12 months ] The QLQ-C30 questionnaire includes 30 questions comprising five functioning scales (physical, role, emotional, cognitive and social

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>